PRIMING REGIMENTS BASED ON IDARUBICIN, OR ACLACINOMYCIN OR PIRARUBICIN COMBINING WITH CYTARABINE AND G-CSF FOR REINDUCTION OF REFRACTORY/RELAPSED ALL
(Abstract release date: 05/19/16)
EHA Library. He G. 06/09/16; 134519; PB1619
Dr. Guangsheng He
Contributions
Contributions
Abstract
Abstract: PB1619
Type: Publication Only
Background
Acute lymphoblastic leukemia (ALL) is one of the most common leukemias with complete remission(CR) rate between 70% and 90%. While the refractory/relapsed ALL is more difficult to treat with poor prognosis. CAG regiment was used for for 6 refractory/relapsed T-cell ALL patients and received high CR rate. So how about CAG regiment for B-cell ALL? What is the situation after the expansion of the cases ? Whether the response rate, adverse reactions would be improved if we use other anthracyclines, such as idarubicin and pirarubicin instead of aclacinomycin for the refractory/relapsed ALL? In our study, the IAG, CAG or PAG regiments were used for refractory/relapsed acute lymphoblasticleukemia respectively The response rate and adverse reactions were elevated.
Aims
To compare the therapeutic effects and adverse reactions of the chemotherapies which were based on idarubicin , aclacinomycin or pirarubicin combining cytarabine and granulocyte-colony stimulating factor as IAG, CAG, and PAG regimens respectively, for refractory/relapsed acute lymphoblastic leukemia.
Methods
The priming reinduction regiment was used to 43 cases with refractory/relapsed acute lymphoblastic leukemia (ALL). IAG, CAG and PAG regiments were non-randomly used to 13, 18 and 12 cases respectively. The clinical effects and adverse reactions of three regiments were evaluated..The factors which might affect the clinical effects were evaluated according to different ages, immunophenotypings and white cell counts.
Results
he overall response rate (ORR) of the priming regiments was 62.8%, with 46.5%(20) of complete remission (CR), 9.6% (7 ) of partial remissions (PR) and 37.2% (16)of non-remission (NR). 7 (53.8%) CR and 2 (15.4%) PR were observed in the IGA group with the ORR at 69.2%. In the CAG group, there were 8 CR cases (44.4%) and 3 PR cases (16.6%) with the ORR at 61%. While in the PAG group 5 CR cases (41.7%) and 2 PR cases (16.6%) with the ORR at 58.3% were observed. There was no statistical difference of ORRs among the three groups (P=0.837); no statistical difference of the ORRs between the patients over and under 60 years old.( 60.0% vs 54.3%; P=0.272); no statistical difference was showed of the ORRs between the T-cell ALL and B-cell ALL patients (68.4% vs 54.1%; P=0.542) and between hyperleukocytic group and non- hyperleukocytic group (50% vs 64.9%; P=0.808). Major adverse reactions, including bone marrow suppression, infection, gastrointestinal reaction and liver function impairment were tolerable after anti-infection, blood cell increasing and transfusion therapy. 6 patients survived and 12 died in the CAG group, 5 cases survived and 8 died in the IAG group, and in the TAG group , the numbers were 7 and 5. No statistical difference of survival time was found when compared in pairs or simultaneously for the three groups.
Conclusion
Preliminary results show that the priming chemotherapy regimens based on small doses of different kinds of anthracyclines were effective on refractory/relapsed ALL patients with good tolerance, minor non-hematological toxicity and side-effects.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Anthracycline, Priming, Refractory
Type: Publication Only
Background
Acute lymphoblastic leukemia (ALL) is one of the most common leukemias with complete remission(CR) rate between 70% and 90%. While the refractory/relapsed ALL is more difficult to treat with poor prognosis. CAG regiment was used for for 6 refractory/relapsed T-cell ALL patients and received high CR rate. So how about CAG regiment for B-cell ALL? What is the situation after the expansion of the cases ? Whether the response rate, adverse reactions would be improved if we use other anthracyclines, such as idarubicin and pirarubicin instead of aclacinomycin for the refractory/relapsed ALL? In our study, the IAG, CAG or PAG regiments were used for refractory/relapsed acute lymphoblasticleukemia respectively The response rate and adverse reactions were elevated.
Aims
To compare the therapeutic effects and adverse reactions of the chemotherapies which were based on idarubicin , aclacinomycin or pirarubicin combining cytarabine and granulocyte-colony stimulating factor as IAG, CAG, and PAG regimens respectively, for refractory/relapsed acute lymphoblastic leukemia.
Methods
The priming reinduction regiment was used to 43 cases with refractory/relapsed acute lymphoblastic leukemia (ALL). IAG, CAG and PAG regiments were non-randomly used to 13, 18 and 12 cases respectively. The clinical effects and adverse reactions of three regiments were evaluated..The factors which might affect the clinical effects were evaluated according to different ages, immunophenotypings and white cell counts.
Results
he overall response rate (ORR) of the priming regiments was 62.8%, with 46.5%(20) of complete remission (CR), 9.6% (7 ) of partial remissions (PR) and 37.2% (16)of non-remission (NR). 7 (53.8%) CR and 2 (15.4%) PR were observed in the IGA group with the ORR at 69.2%. In the CAG group, there were 8 CR cases (44.4%) and 3 PR cases (16.6%) with the ORR at 61%. While in the PAG group 5 CR cases (41.7%) and 2 PR cases (16.6%) with the ORR at 58.3% were observed. There was no statistical difference of ORRs among the three groups (P=0.837); no statistical difference of the ORRs between the patients over and under 60 years old.( 60.0% vs 54.3%; P=0.272); no statistical difference was showed of the ORRs between the T-cell ALL and B-cell ALL patients (68.4% vs 54.1%; P=0.542) and between hyperleukocytic group and non- hyperleukocytic group (50% vs 64.9%; P=0.808). Major adverse reactions, including bone marrow suppression, infection, gastrointestinal reaction and liver function impairment were tolerable after anti-infection, blood cell increasing and transfusion therapy. 6 patients survived and 12 died in the CAG group, 5 cases survived and 8 died in the IAG group, and in the TAG group , the numbers were 7 and 5. No statistical difference of survival time was found when compared in pairs or simultaneously for the three groups.
Conclusion
Preliminary results show that the priming chemotherapy regimens based on small doses of different kinds of anthracyclines were effective on refractory/relapsed ALL patients with good tolerance, minor non-hematological toxicity and side-effects.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Anthracycline, Priming, Refractory
Abstract: PB1619
Type: Publication Only
Background
Acute lymphoblastic leukemia (ALL) is one of the most common leukemias with complete remission(CR) rate between 70% and 90%. While the refractory/relapsed ALL is more difficult to treat with poor prognosis. CAG regiment was used for for 6 refractory/relapsed T-cell ALL patients and received high CR rate. So how about CAG regiment for B-cell ALL? What is the situation after the expansion of the cases ? Whether the response rate, adverse reactions would be improved if we use other anthracyclines, such as idarubicin and pirarubicin instead of aclacinomycin for the refractory/relapsed ALL? In our study, the IAG, CAG or PAG regiments were used for refractory/relapsed acute lymphoblasticleukemia respectively The response rate and adverse reactions were elevated.
Aims
To compare the therapeutic effects and adverse reactions of the chemotherapies which were based on idarubicin , aclacinomycin or pirarubicin combining cytarabine and granulocyte-colony stimulating factor as IAG, CAG, and PAG regimens respectively, for refractory/relapsed acute lymphoblastic leukemia.
Methods
The priming reinduction regiment was used to 43 cases with refractory/relapsed acute lymphoblastic leukemia (ALL). IAG, CAG and PAG regiments were non-randomly used to 13, 18 and 12 cases respectively. The clinical effects and adverse reactions of three regiments were evaluated..The factors which might affect the clinical effects were evaluated according to different ages, immunophenotypings and white cell counts.
Results
he overall response rate (ORR) of the priming regiments was 62.8%, with 46.5%(20) of complete remission (CR), 9.6% (7 ) of partial remissions (PR) and 37.2% (16)of non-remission (NR). 7 (53.8%) CR and 2 (15.4%) PR were observed in the IGA group with the ORR at 69.2%. In the CAG group, there were 8 CR cases (44.4%) and 3 PR cases (16.6%) with the ORR at 61%. While in the PAG group 5 CR cases (41.7%) and 2 PR cases (16.6%) with the ORR at 58.3% were observed. There was no statistical difference of ORRs among the three groups (P=0.837); no statistical difference of the ORRs between the patients over and under 60 years old.( 60.0% vs 54.3%; P=0.272); no statistical difference was showed of the ORRs between the T-cell ALL and B-cell ALL patients (68.4% vs 54.1%; P=0.542) and between hyperleukocytic group and non- hyperleukocytic group (50% vs 64.9%; P=0.808). Major adverse reactions, including bone marrow suppression, infection, gastrointestinal reaction and liver function impairment were tolerable after anti-infection, blood cell increasing and transfusion therapy. 6 patients survived and 12 died in the CAG group, 5 cases survived and 8 died in the IAG group, and in the TAG group , the numbers were 7 and 5. No statistical difference of survival time was found when compared in pairs or simultaneously for the three groups.
Conclusion
Preliminary results show that the priming chemotherapy regimens based on small doses of different kinds of anthracyclines were effective on refractory/relapsed ALL patients with good tolerance, minor non-hematological toxicity and side-effects.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Anthracycline, Priming, Refractory
Type: Publication Only
Background
Acute lymphoblastic leukemia (ALL) is one of the most common leukemias with complete remission(CR) rate between 70% and 90%. While the refractory/relapsed ALL is more difficult to treat with poor prognosis. CAG regiment was used for for 6 refractory/relapsed T-cell ALL patients and received high CR rate. So how about CAG regiment for B-cell ALL? What is the situation after the expansion of the cases ? Whether the response rate, adverse reactions would be improved if we use other anthracyclines, such as idarubicin and pirarubicin instead of aclacinomycin for the refractory/relapsed ALL? In our study, the IAG, CAG or PAG regiments were used for refractory/relapsed acute lymphoblasticleukemia respectively The response rate and adverse reactions were elevated.
Aims
To compare the therapeutic effects and adverse reactions of the chemotherapies which were based on idarubicin , aclacinomycin or pirarubicin combining cytarabine and granulocyte-colony stimulating factor as IAG, CAG, and PAG regimens respectively, for refractory/relapsed acute lymphoblastic leukemia.
Methods
The priming reinduction regiment was used to 43 cases with refractory/relapsed acute lymphoblastic leukemia (ALL). IAG, CAG and PAG regiments were non-randomly used to 13, 18 and 12 cases respectively. The clinical effects and adverse reactions of three regiments were evaluated..The factors which might affect the clinical effects were evaluated according to different ages, immunophenotypings and white cell counts.
Results
he overall response rate (ORR) of the priming regiments was 62.8%, with 46.5%(20) of complete remission (CR), 9.6% (7 ) of partial remissions (PR) and 37.2% (16)of non-remission (NR). 7 (53.8%) CR and 2 (15.4%) PR were observed in the IGA group with the ORR at 69.2%. In the CAG group, there were 8 CR cases (44.4%) and 3 PR cases (16.6%) with the ORR at 61%. While in the PAG group 5 CR cases (41.7%) and 2 PR cases (16.6%) with the ORR at 58.3% were observed. There was no statistical difference of ORRs among the three groups (P=0.837); no statistical difference of the ORRs between the patients over and under 60 years old.( 60.0% vs 54.3%; P=0.272); no statistical difference was showed of the ORRs between the T-cell ALL and B-cell ALL patients (68.4% vs 54.1%; P=0.542) and between hyperleukocytic group and non- hyperleukocytic group (50% vs 64.9%; P=0.808). Major adverse reactions, including bone marrow suppression, infection, gastrointestinal reaction and liver function impairment were tolerable after anti-infection, blood cell increasing and transfusion therapy. 6 patients survived and 12 died in the CAG group, 5 cases survived and 8 died in the IAG group, and in the TAG group , the numbers were 7 and 5. No statistical difference of survival time was found when compared in pairs or simultaneously for the three groups.
Conclusion
Preliminary results show that the priming chemotherapy regimens based on small doses of different kinds of anthracyclines were effective on refractory/relapsed ALL patients with good tolerance, minor non-hematological toxicity and side-effects.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Anthracycline, Priming, Refractory
{{ help_message }}
{{filter}}